News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Receptos to Deliver Scientific Presentations About RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)


10/2/2013 9:48:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations about RPC1063 at the annual meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark during October 2-5, 2013. RPC1063 is the Company's lead sphingosine 1-phosphate 1 receptor (S1P1R) modulator in Phase 2 development for both relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Receptos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES